Sutro Biopharma Stock Price Prediction
| STRO Stock | USD 2.58 0.05 1.98% |
Oversold Vs Overbought
68
Oversold | Overbought |
EPS Estimate Next Quarter (0.74) | EPS Estimate Current Year (3.10) | EPS Estimate Next Year (3.46) | Wall Street Target Price 12 | EPS Estimate Current Quarter (0.73) |
Using Sutro Biopharma hype-based prediction, you can estimate the value of Sutro Biopharma from the perspective of Sutro Biopharma response to recently generated media hype and the effects of current headlines on its competitors.
The fear of missing out, i.e., FOMO, can cause potential investors in Sutro Biopharma to buy its stock at a price that has no basis in reality. In that case, they are not buying Sutro because the equity is a good investment, but because they need to do something to avoid the feeling of missing out. On the other hand, investors will often sell stocks at prices well below their value during bear markets because they need to stop feeling the pain of losing money.
Sutro Biopharma after-hype prediction price | USD 2.52 |
There is no one specific way to measure market sentiment using hype analysis or a similar predictive technique. This prediction method should be used in combination with more fundamental and traditional techniques such as stock price forecasting, technical analysis, analysts consensus, earnings estimates, and various momentum models.
Sutro |
Sutro Biopharma After-Hype Price Prediction Density Analysis
As far as predicting the price of Sutro Biopharma at your current risk attitude, this probability distribution graph shows the chance that the prediction will fall between or within a specific range. We use this chart to confirm that your returns on investing in Sutro Biopharma or, for that matter, your successful expectations of its future price, cannot be replicated consistently. Please note, a large amount of money has been lost over the years by many investors who confused the symmetrical distributions of Stock prices, such as prices of Sutro Biopharma, with the unreliable approximations that try to describe financial returns.
Next price density |
| Expected price to next headline |
Sutro Biopharma Estimiated After-Hype Price Volatility
In the context of predicting Sutro Biopharma's stock value on the day after the next significant headline, we show statistically significant boundaries of downside and upside scenarios based on Sutro Biopharma's historical news coverage. Sutro Biopharma's after-hype downside and upside margins for the prediction period are 0.13 and 7.67, respectively. We have considered Sutro Biopharma's daily market price in relation to the headlines to evaluate this method's predictive performance. Remember, however, there is no scientific proof or empirical evidence that news-based prediction models outperform traditional linear, nonlinear models or artificial intelligence models to provide accurate predictions consistently.
Current Value
Sutro Biopharma is relatively risky at this time. Analysis and calculation of next after-hype price of Sutro Biopharma is based on 3 months time horizon.
Sutro Biopharma Stock Price Prediction Analysis
Have you ever been surprised when a price of a Company such as Sutro Biopharma is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Sutro Biopharma backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the Stock price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with Sutro Biopharma, there might be something going there, and it might present an excellent short sale opportunity.
| Expected Return | Period Volatility | Hype Elasticity | Related Elasticity | News Density | Related Density | Expected Hype |
0.93 | 5.19 | 0.01 | 0.21 | 6 Events / Month | 4 Events / Month | In about 6 days |
| Latest traded price | Expected after-news price | Potential return on next major news | Average after-hype volatility | ||
2.58 | 2.52 | 0.40 |
|
Sutro Biopharma Hype Timeline
Sutro Biopharma is at this time traded for 2.58. The entity has historical hype elasticity of -0.01, and average elasticity to hype of competition of 0.21. Sutro is projected to decline in value after the next headline, with the price expected to drop to 2.52. The average volatility of media hype impact on the company price is over 100%. The price decrease on the next news is expected to be -0.4%, whereas the daily expected return is at this time at -0.93%. The volatility of related hype on Sutro Biopharma is about 2272.99%, with the expected price after the next announcement by competition of 2.79. About 77.0% of the company shares are owned by institutional investors. The company has price-to-book ratio of 1.98. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Sutro Biopharma has Price/Earnings To Growth (PEG) ratio of 0.12. The entity recorded a loss per share of 1.55. The firm had not issued any dividends in recent years. Given the investment horizon of 90 days the next projected press release will be in about 6 days. Check out Sutro Biopharma Basic Forecasting Models to cross-verify your projections.Sutro Biopharma Related Hype Analysis
Having access to credible news sources related to Sutro Biopharma's direct competition is more important than ever and may enhance your ability to predict Sutro Biopharma's future price movements. Getting to know how Sutro Biopharma's peers react to changing market sentiment, related social signals, and mainstream news is a great way to find investing opportunities and time the market. The summary table below summarizes the essential lagging indicators that can help you analyze how Sutro Biopharma may potentially react to the hype associated with one of its peers.
| HypeElasticity | NewsDensity | SemiDeviation | InformationRatio | PotentialUpside | ValueAt Risk | MaximumDrawdown | |||
| ZVSA | ZyVersa Therapeutics | (0.01) | 5 per month | 0.00 | (0.14) | 9.17 | (10.36) | 78.93 | |
| SONN | Sonnet Biotherapeutics Holdings | 1.15 | 7 per month | 0.00 | (0.13) | 12.31 | (9.79) | 37.58 | |
| ZURA | Zura Bio Limited | 0.03 | 9 per month | 0.00 | (0.05) | 7.95 | (7.94) | 30.69 | |
| PHIO | Phio Pharmaceuticals Corp | 0.18 | 6 per month | 0.00 | (0.05) | 11.78 | (10.38) | 36.22 | |
| RNAZ | Transcode Therapeutics | 0.04 | 2 per month | 6.52 | 0.07 | 22.00 | (11.43) | 68.80 | |
| QNRX | Quoin Pharmaceuticals Ltd | (0.02) | 9 per month | 6.73 | 0.05 | 17.65 | (9.68) | 74.46 |
Sutro Biopharma Additional Predictive Modules
Most predictive techniques to examine Sutro price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for Sutro using various technical indicators. When you analyze Sutro charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
About Sutro Biopharma Predictive Indicators
The successful prediction of Sutro Biopharma stock price could yield a significant profit to investors. But is it possible? The efficient-market hypothesis suggests that all published stock prices of traded companies, such as Sutro Biopharma, already reflect all publicly available information. This academic statement is a fundamental principle of many financial and investing theories used today. However, the typical investor usually disagrees with a 'textbook' version of this hypothesis and continually tries to find mispriced stocks to increase returns. We use internally-developed statistical techniques to arrive at the intrinsic value of Sutro Biopharma based on analysis of Sutro Biopharma hews, social hype, general headline patterns, and widely used predictive technical indicators.
We also calculate exposure to Sutro Biopharma's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Sutro Biopharma's related companies. | 2021 | 2022 | 2023 | 2024 (projected) | Graham Number | 17.04 | 15.04 | 9.97 | 9.47 | Receivables Turnover | 4.97 | 9.52 | 4.26 | 4.05 |
Story Coverage note for Sutro Biopharma
The number of cover stories for Sutro Biopharma depends on current market conditions and Sutro Biopharma's risk-adjusted performance over time. The coverage that generates the most noise at a given time depends on the prevailing investment theme that Sutro Biopharma is classified under. However, while its typical story may have numerous social followers, the rapid visibility can also attract short-sellers, who usually are skeptical about Sutro Biopharma's long-term prospects. So, having above-average coverage will typically attract above-average short interest, leading to significant price volatility.
Contributor Headline
Latest Perspective From Macroaxis
Sutro Biopharma Short Properties
Sutro Biopharma's future price predictability will typically decrease when Sutro Biopharma's long traders begin to feel the short-sellers pressure to drive the price lower. The predictive aspect of Sutro Biopharma often depends not only on the future outlook of the potential Sutro Biopharma's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Sutro Biopharma's indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 60.2 M | |
| Cash And Short Term Investments | 375.6 M |
Check out Sutro Biopharma Basic Forecasting Models to cross-verify your projections. To learn how to invest in Sutro Stock, please use our How to Invest in Sutro Biopharma guide.You can also try the Competition Analyzer module to analyze and compare many basic indicators for a group of related or unrelated entities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Sutro Biopharma. If investors know Sutro will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Sutro Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.55) | Revenue Per Share 2.253 | Quarterly Revenue Growth (0.50) | Return On Assets (0.18) | Return On Equity (1.11) |
The market value of Sutro Biopharma is measured differently than its book value, which is the value of Sutro that is recorded on the company's balance sheet. Investors also form their own opinion of Sutro Biopharma's value that differs from its market value or its book value, called intrinsic value, which is Sutro Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Sutro Biopharma's market value can be influenced by many factors that don't directly affect Sutro Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Sutro Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Sutro Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Sutro Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.